Absci Corp
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to design differentiated antibody therapeutics. Its preclinical development programs include ABS-101 for the treatment of inflammatory bowel disease; ABS-201 for treating androgenic alopecia; ABS-301 for the treat… Read more
Absci Corp (ABSI) - Total Liabilities
Latest total liabilities as of September 2025: $34.65 Million USD
Based on the latest financial reports, Absci Corp (ABSI) has total liabilities worth $34.65 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Absci Corp - Total Liabilities Trend (2019–2024)
This chart illustrates how Absci Corp's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Absci Corp Competitors by Total Liabilities
The table below lists competitors of Absci Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CICOR TECHNOL.NAM. SF 10
F:CRLN
|
Germany | €347.12 Million |
|
Nu Skin Enterprises Inc
NYSE:NUS
|
USA | $624.61 Million |
|
Maxvision Technology Corp
SHE:002990
|
China | CN¥1.30 Billion |
|
SAMPYO Cement Co. Ltd
KQ:038500
|
Korea | ₩660.87 Billion |
|
Wenzhou Hongfeng Electrical Alloy Co Ltd
SHE:300283
|
China | CN¥2.38 Billion |
|
Beijing Kawin Technology Share-holding Co Ltd
SHG:688687
|
China | CN¥1.04 Billion |
|
Hotai Finance Corp
TW:6592
|
Taiwan | NT$281.09 Billion |
|
Beijing Hanyi Innovation Technology Co. Ltd. A
SHE:301270
|
China | CN¥191.34 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Absci Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.89 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Absci Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Absci Corp (2019–2024)
The table below shows the annual total liabilities of Absci Corp from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $34.48 Million | -16.16% |
| 2023-12-31 | $41.12 Million | -11.74% |
| 2022-12-31 | $46.59 Million | -22.46% |
| 2021-12-31 | $60.09 Million | +178.65% |
| 2020-12-31 | $21.56 Million | -64.43% |
| 2019-12-31 | $60.63 Million | -- |